Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pagibaximab

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
INTRODUCTION Advances in modern medicine have given very low birth weight (VLBW) infants a better chance of survival; however… Expand
  • table 3
  • table 4
  • table 1
  • table 5
  • table 6
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Pagibaximab, a human chimeric monoclonal antibody developed against lipoteichoic acid, was effective against… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2009
2009
Staphylococcal sepsis is a major cause of morbidity and mortality in very-low-birth-weight (VLBW) infants. A human chimeric… Expand
Is this relevant?
2009
2009
A chimerized (murine/human) monoclonal antibody (pagibaximab) against lipoteichoic acid (LTA) and protective in animal models for… Expand
Is this relevant?
Review
2009
Review
2009
BACKGROUND Nosocomial infection is a major problem affecting the immediate health and long-term outcome of preterm and very low… Expand
Is this relevant?
2008
2008
The ability to measure the opsonic activity of antibody may be critical in choosing among potential therapeutic candidates. It… Expand
Is this relevant?
Review
2007
Review
2007
Staphylococci, especially coagulase negative staphylococci (CONS), are responsible for over 75 % of late-onset infections in very… Expand
Is this relevant?